With many biologics now available for patients with moderate-to-severe plaque psoriasis, providers may find themselves transitioning among them to optimize treatment and improve quality of life, according to Ron Vender, M.D. In this article, he offers insight into how to switch appropriately.
A study showing differences in baseline characteristics between responders to anti-tumor necrosis factor (anti-TNF) therapy and insufficient responders may be helpful to dermatologists as they consider treatment for patients with moderate-to-severe psoriasis, according to the investigators.
